Insitro is a San Francisco-based biotechnology company with a focus on using artificial intelligence and other technologies for the research and development of drugs for medical patients. It uses machine learning and high-throughput biology to develop its therapeutics.
The company has developed predictive models which are intended to be used to provide insight into which drugs will be successful and for which group of people. These models use information from patients such as genetic, phenotypic, and clinical data to conduct analyses. It uses the results from these analyses to create cell-based disease models. Machine learning is applied in order to differentiate between cell states. The use of in vitro models of disease combined with in silico machine learning models is where the name of the company, insitro, derives. The company uses these technologies to make predictions about interventions that may work for the diseases,
Insitro's technology has been used to research and develop drugs for diseases such as non-alcoholic fatty liver disease. It can also be used to discover subtypes of diseases, such as Alzheimer's and diabetes.
Insitro raises a $143,210,951 series B round from Third Rock Ventures, Andreessen Horowitz, HOF Capital, ARCH Venture Partners, Casdin Capital, Foresite Capital, BlackRock, Alexandria Venture Investments, Canada Pension Plan Investment Board, Two Sigma Ventures, T. Rowe Price and GV.
Combining AI and biology could solve drug discovery's biggest problems
June 14, 2020
insitro Announces $143 Million Raised in Series B Financing
May 26, 2020